Maryanne Maunsell Farris's most recent trade in Haemonetics Corp. was a trade of 1,291 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 17, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Haemonetics Corp. | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 1,291 | 1,291 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 587 | 1,144 (0%) | 0% | - | Common Stock | |
Haemonetics Corp. | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.49 per share. | 15 May 2024 | 73 | 557 (0%) | 0% | 96.5 | 7,044 | Common Stock |
Haemonetics Corp. | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 1,425 | 1,425 | - | - | Non-qualified Stock Option (Right to Buy) | |
Haemonetics Corp. | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 630 | 630 (0%) | 0% | - | Common Stock |